Dr. Craig Blackstone, M.D., Ph.D., appointed as Chair, Asha Therapeutics’ Scientific Advisory Board
Asha Therapeutics www.ashatherapeutics.com announced today that it has appointed Dr. Craig Blackstone, Chief of the Movement Disorders...
NOVEL COMPOUNDS FOR TOMORROW'S CURES
THE SCIENCE
At Asha Therapeutics we are developing novel, first-in-class compounds targeting the point of greatest therapeutic impact for diseases with high unmet medical need. We have active programs in neuroscience for therapeutic intervention in neurodegenerative diseases including Parkinson's Disease (PD), Alzheimer's Disease (AD), and Amyotrophic Lateral Sclerosis (ALS), post-viral illnesses such as Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) and Long Haul COVID, as well as Ischemic Stroke and Neuro-oncology.
Asha's Focus: The Big Four Neurological Diseases
THE
PRISM™ PLATFORM
Central to Asha's efforts to identify and drug difficult to hit targets with high disease relevance is our proprietary PRISM™ platform. PRISM™ is a novel physics-based drug design platform.
LATEST NEWS
